Programme
Monday, September 2
07:30 – 10:00
Registration
10:00-10:30
Opening
Martin Fusek (Director IOCB Tech)
Jan Konvalinka (Director of IOCB Prague)
Milan Pospíšil (Rector of UCT Prague)
David Honys (Council Member of the Czech Academy of Science)
10:30-11:10
Petra Ménová, UCT Prague, Czech Republic
How are new drugs born?
11:10-11:50
Deborah Fass, Weizmann Institute of Science, Rehovot, Israel
Structures of mucin glycoproteins inspire molecular methods for modulating mucosal functions
11:50-12:30
Milan Vrábel, IOCB Prague, Czech Republic
Chemical engineering of cell surfaces for cancer immunotherapy
12:30-13:50
Lunch
13:50-14:30
Marek Šťastný, Medical Department, Bristol-Myers Squibb, Czech Republic
Cancer immunotherapies based on anti-PD1: clinical perspectives and challenges
14:30-15:10
Stella Vukelic, AbbVie, Ludwigshafen, Germany
Molecular obesity – An addiction in drug discovery?
15:10-15:50
Jitka Riedl, Bicycle Therapeutics, Cambridge, UK
Attacking from all angles: EphA2 targeting Bicycle® peptides for precision guided cancer therapy via multiple approaches
15:50-16:20
Coffee break
16:20-17:00
David Margulies, Weizmann Institute of Science, Rehovot, Israel
Detecting proteins and protein-inhibitor interactions with ‘turn-on’ fluorescent molecular probes: design principles and applications in medical diagnosis, cell imaging and drug discovery
17:00-17:40
Andrea Brancale, UCT Prague, Czech Republic
Kick-start new drug design projects using computer-aided drug design
19:00
Welcome party
Tuesday, September 3
08:30 – 09:00
Registration
09:00-09:40
Peter H. Seeberger, Max Planck Institute of Colloids and Iterfaces, Potsdam, Germany
Freie Universität, Berlin, Germany
Synthetic glycans as basis for vaccines, therapeutic antibodies and diagnostics
09:40-10:20
Christoph Rademacher, University of Vienna, Austria
Cell-specific targeted delivery of therapeutics
10:20-10:50
Coffee break
10:50-11:30
Frank Wagner, Charité, Berlin, Germany
Focus on early clinical trials
11:30-12:10
Oliviana Calin-Eller, E. Blum & Co. AG, Zurich, Switzerland
Patents: Why? What? How?
12:10-12:50
Valery Khrizanovsky, Weizmann Institute of Science, Rehovot, Israel
Senescent cells in aging and age-related disease: the good, the bad and the ugly
12:50-14:10
Lunch
14:10-15:40
Spin-offs: roundtable discussion
Panelists: Oliviana Calin-Eller, Valery Khrizanovsky, Christoph Rademacher, David Stíbal, Frank Wagner
Host: Aleš Vlk
15:50-17:30
Poster session + refreshments
Wednesday, September 4
08:30 – 09:00
Registration
09:00-09:40
Stephan Bachmann, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Catalysis as key technology for the synthesis and scale-up of APIs and their intermediates
09:40-10:20
Camille Correia, Merck Electronics KGaA, Darmstadt, Germany
Modular continuous automation for laboratories and production
10:20-10:50
Coffee break
10:50-11:30
Martina Benešová-Schäfer, German Cancer Research Center, Heidelberg, Germany
Pharmaceutical radiochemistry in modern nuclear medicine
11:30-12:10
Sima Lev, Weizmann Institute of Science, Rehovot, Israel
Triple-negative breast cancer: heterogeneity and targeted therapy
12:10-12:50
Kateřina Vávrová, Faculty of Pharmacy Hradec Kralove, Charles University, Czech Republic
Ceramides in the skin: extraordinary lipids for an extraordinary barrier
12:50-14:00
Lunch
14:00-18:00
Prague city tour
18:00
Social evening – Karolinum
Thursday, September 5
08:30 – 09:00
Registration
09:00-09:40
Jan Konvalinka, IOCB Prague, Czech Republic
Chemical-biology tools in drug development
09:40-10:20
Daniela Angst, Novartis, Basel, Switzerland
Remibrutinib, a covalent BTK inhibitor with best-in-class selectivity: discovery and clinical results
10:20-10:50
Coffee break
10:50-11:30
Henry Maun, Genentech, South San Francisco, USA
From bench to bedside: Understanding mechanisms of inhibitory anti-tryptase antibodies for the treatment of asthma.
11:30-12:10
Graciela Andrei, Rega Institute for Medical Research, KU Leuven, Belgium
Herpesvirus drug-resistance: challenges and opportunities
12:10-13:30
Lunch
13:30-14:10
Gideon Schreiber, Weizmann Institute of Science, Rehovot, Israel
Reversing protonation of weakly basic drugs greatly enhances intracellular diffusion and decreases lysosomal sequestration
14:10-14:50
Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel
Overcoming resistance of lung cancer to tyrosine kinase inhibitors
14:50-15:30
Richard Clarkson, Cardiff University, UK
Targeting cells responsible for metastatic disease
15:30-18:00
Excursions: UCT Brewery, IOCB labs
Friday, September 6
08:30 – 09:00
Registration
09:00-09:40
Pavlína Řezáčová, IOCB Prague, Czech Republic
Structure-assisted design of enzyme inhibitors
09:40-10:20
Igor Ulitsky, Weizmann Institute of Science, Rehovot, Israel
Therapeutic targeting of RNA molecules
10:20-10:50
Coffee break
10:50-11:30
Jitka Palich Fučíková, Sotio Biotech Department of Immunology, 2nd Medical school, Charles University, Czech Republic
The role of immune system in cancer therapy
11:30-12:10
Menachem Rubinstein, Weizmann Institute of Science, Rehovot, Israel
Directing viral vectors to specific cell types for oncolytic virotherapy and in vivo gene therapy
12:10-13:30
Lunch
13:30-14:10
Jan Skácel, IOCB Prague, Czech Republic
A postgraduate student’s perspective on drug discovery in academia: Development of PNP inhibitors
14:10-14:50
Kvido Stříšovský, IOCB Prague, Czech Republic
The elusive mechanisms of unexpected regulators of inflammatory and growth factor signalling
14:50-15:00
Closing, best poster award
